GKOS
Glaukos Corp
NYSE: GKOS · HEALTHCARE · MEDICAL DEVICES
$116.96
-2.23% today
Updated 2026-04-29
Market cap
$7.00B
P/E ratio
—
P/S ratio
13.80x
EPS (TTM)
$-3.28
Dividend yield
—
52W range
$73 – $130
Volume
0.7M
WallStSmart proprietary scores
44
out of 100
Grade: D
Sell
Investment rating
10.0
Growth
A+5.8
Quality
C+2.0
Profitability
F5.0
Valuation
C+3/9
Piotroski F-Score
Weak
1.5
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$138.92
+18.78%
12-Month target
—
—
Intrinsic (DCF)
$111.30
Margin of safety
+2.04%
3 Strong Buy10 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Free cash flow $3.93M — positive
+ Revenue growth 35.70% QoQ
Risks
- Piotroski 3/9 — weak financial health
- Altman Z 1.49 — distress zone
- Thin margins at -37.00%
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $282.86M | $314.71M | $383.48M | $507.44M | $507.44M |
| Net income | $-99.19M | $-134.66M | $-146.37M | $-187.69M | $-133.66M |
| EPS | — | — | — | — | $-3.28 |
| Free cash flow | $-63.35M | $-78.01M | $-67.62M | $-54.01M | $3.93M |
| Profit margin | -35.07% | -42.79% | -38.17% | -36.99% | -37.00% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-10 | NAVRATIL, TOMAS | Sale | 1,237 | $116.72 |
| 2026-04-10 | NAVRATIL, TOMAS | Sale | 614 | $119.35 |
| 2026-04-10 | NAVRATIL, TOMAS | Sale | 210 | $117.45 |
Peer comparison
Smart narrative
Glaukos Corp trades at $116.96. Our Smart Value Score of 44/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 1.49, it sits in the distress. TTM revenue stands at $507.44M. with profit margins at -37.00%. Our DCF model estimates intrinsic value at $111.30.
Frequently asked questions
What is Glaukos Corp's stock price?
Glaukos Corp (GKOS) trades at $116.96.
Is Glaukos Corp overvalued?
Smart Value Score 44/100 (Grade D, Sell). DCF value $111.30.
What is the price target of Glaukos Corp (GKOS)?
The analyst target price is $138.92, representing +18.8% upside from the current price of $116.96.
What is the intrinsic value of Glaukos Corp (GKOS)?
Based on our DCF model, intrinsic value is $111.30, a +2.0% margin of safety versus $116.96.
What is Glaukos Corp's revenue?
TTM revenue is $507.44M.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
1.49 — distress.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio13.80x
ROE-26.40%
Beta0.78
50D MA$113.46
200D MA$101.49
Shares out0.06B
Float0.06B
Short ratio—
Avg volume0.7M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—